Table 2: Characteristics of community studies.

Duration
TreatmentDose (IU)RegimenSubjectsFemale (%)Age mean (SD) or median (range)Vitamin D (nmol/L)# mean (SD) or median (IQR)Ca+ intake (mg/day)
mean (SD) or median (IQR)

RECORDMedian 45 months (range 24–62)All52928577 (6)NANA
D3800 dailyD/CaD264977 (6)NANA
PCa/P264377 (6)NANA
PorthouseMedian 25 months (range 18–42)All3314100NA
D3800 dailyCaD132177 (5)NA1075 (338)
PP199377 (5)NA1084 (346)
WHI
subgroup
7 years (mean)All6340100>70NA1150
D3400 dailyCaD3173NANA
PP3167NANA
Kyphos
substudy
1 yearAll12010075 (3)68 (29)1010 (349)
D21000 dailyCaD3975 (3)70 (26)927 (295)
PP
CaP
41
40
75 (3)
74 (2)
67 (34)
67 (26)
1046 (340)
1054 (398)
Zhu5 yearsAll30210044 (13)1097 (495)
D21000 dailyCaD15177 (4)45 (13)1109 (503)
PCaP15177 (5)44 (13)1087 (410)
Lips-combined3.5 years maximumAll25787480 (6)NA
D3400 dailyD129180 (6)27
19–36
NA
PP128780 (6)26
19–37
NA
Heikinheimo community2–5 yearsAll47977NANA
D2150000–300000 yearly*D19987NANA
PP28086NANA
Smith3 yearsAll94405479
77–83
141 (59)625 (231)
D2300000 yearly*D472779
77–83
NANA
PP471379
77–83
NANA

IM treatment. #Divide by 2.5 for ng/mL. IU: international units; D2: ergocalciferol; D3: cholecalciferol; D: vitamin D only; CaD: calcium and vitamin D; Ca: calcium only; P: placebo or control; NA: not available.